AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04385849 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex
Study NCT04385849 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Sterile saline solution
Study NCT03373526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: The aerobic physical training will be perform using a cycle ergometer, during 20 minutes daily, five times a week, with moderate intensity (50-70% of reserve heart rate).
Study NCT01423682 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Eccentric exercise
Description: Patients and healthy subjects will perform an eccentric exercise during which a weight is lifted along the body and lowered with an extended arm at a slow speed. Weight is determined, based on pain in patients and based on force in healthy subjects.
Study NCT01423682 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric exercise
Description: Patients and healthy subjects will perform an eccentric exercise during which a weight is lifted along the body and lowered with an extended arm at a slow speed. Weight is determined, based on pain in patients and based on force in healthy subjects.
Study NCT00710606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NuvaRing
Description: Obese subjects (BMI 30-39.9) will receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
Study NCT00710606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NuvaRing
Description: Normal weight subjects will also receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
Study NCT03652779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecarfarin 10mg
Description: Tecarfarin 10mg tablets
Study NCT03652779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecarfarin 20mg
Description: two tecarfarin 10mg tablets
Study NCT03652779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecarfarin 30mg
Description: three tecarfarin 10mg tablets
Study NCT03652779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecarfarin 40mg
Description: four tecarfarin 10mg tablets
Study NCT02298361 — intervention group
Intervention type: OTHER
Intervention: Health insurance outreach IT tools
Description: IT tools that support Community Health Centers in children's health insurance outreach efforts (insurance outreach IT tools), adapted from tools proven to support chronic disease management.
Study NCT01564368 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diffusion-weighted magnetic resonance imaging
Description: diffusion-weighted magnetic resonance imaging examination and subsequent radiologist interpretation
Study NCT02991482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (MK-3475) is a potent and highly selective humanised monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade enhances functional activity of the target lymphocytes to facilitate tumour regression and ultimately immune rejection.
Study NCT02991482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication. The process arrests tumour growth, as new nucleosides cannot be attached to the faulty nucleoside, resulting in apoptosis (cellular suicide).
Study NCT02991482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Vinorelbine is a vinca alkaloid cytotoxic chemotherapy that is available in intravenous and oral preparations with EMA licenses in lung cancer and breast cancer. Vinorelbine blocks mitosis in phase G2-M, causing cell death in interphase or at the following mitosis.
Study NCT02879448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amulet Left Atrial Appendage Occluder
Description: Transcatheter left atrial appendage closure
Study NCT02879448 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WATCHMAN Left Atrial Appendage Closure
Description: Transcatheter left atrial appendage closure
Study NCT01696331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Reminder
Description: Sent TM reminder at beginning and end of each month that corresponded to required lab frequency. Patients were able to send autoresponses.
Study NCT02301351 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Graphic Warning Label
Description: All packs provided will include FDA-approved graphic warning labels
Study NCT02301351 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Text Warning Label
Description: All packs provided will include standard text warning labels
Study NCT02462902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% albumin Infusion
Description: colloid, 5% albumin (250 ml over 15 to 30 minutes).
Study NCT02462902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% sodium chloride solution
Description: 0.9% sodium chloride solution (total of 30ml/kg over 15 to 30 minutes)
Study NCT04439643 — intervention group
Intervention type: DEVICE
Intervention: vascuCAP
Description: time to event and phenotype classification model
Study NCT01713725 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: * Two injections will be administered the first two weeks~* The following three injections will be administered every four weeks Consequently, we will administer 5 doses within 14 weeks
Study NCT01713725 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Omalizumab
Description: * Two injections will be administered the first two weeks~* The following three injections will be administered every four weeks Consequently, we will administer 5 doses within 14 weeks
Study NCT01713725 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: * Two injections will be administered the first two weeks~* The following three injections will be administered every four weeks Consequently, we will administer 5 doses within 14 weeks
Study NCT01713725 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Two injections will be administered the first two weeks~* The following three injections will be administered every four weeks Consequently, we will administer 5 doses within 14 weeks
Study NCT01750879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peanut Flour
Description: Peanut Flour
Study NCT01750879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oat Flour
Description: Oat Flour
Study NCT01439607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone marrow and blood sampling
Description: Bone marrow and blood sampling
Study NCT04167241 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Before and after right pneumonectomy or bi-lobectomy patients will receive echocardiography
Study NCT04570917 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online educational intervention to reduce ageism
Description: Participants in this group will go over multiple short videos covering the following content:1). Myths about aging, 2). Ageism and its negative effects, 3). Distorted views about aging among young adults, 4). Ageism during the COVID-19 pandemic, and 5). importance of reducing ageism among healthcare professionals. These will be multiple videos posted on the LMS (Blackboard). At the end of the lesson, they will be asked to briefly write what they learned on Blackboard as an assignment.
Study NCT04570917 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online educational intervention to enhance cultural competance
Description: Participants in the control group will go over multiple short videos covering the following content: 1). Myths about cultural competence, 2) Cultural competence for health care professionals including dietitians, 3). Connecting culture and food, and 4). Importance of cultural competence in sports dietitians. At the end of the lesson, they will be asked to briefly write what they learned. These will be multiple videos posted on the LMS (Blackboard). At the end of the lesson, they will be asked to briefly write what they learned on Blackboard as an assignment.
Study NCT01342458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flexible footwear
Description: The patients of the Intervention Group (IG) will be use over 6 month a flexible and non-heeled footwear (Moleca; Calçados Beira Rio S.A., Novo Hamburgo, Rio Grande do Sul, Brazil) is a women's flexible flat walking shoe, without heels, with an anti-slip rubber sole, 5-mm thin, with a 3 mm internal wedge of ethylene vinyl acetate, made out of dubbed canvas. It had a mean weight of 172 ± 19.6 g, ranging from 142 to 193 g depending upon the size.
Study NCT02946840 — intervention group
Intervention type: DEVICE
Intervention: FNA with 25 G Beacon needle
Study NCT02659787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2mg Buprenorphine
Description: Sublingual buprenorphine tablets (0.2mg)
Study NCT02659787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01936701 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: bilateral cataract surgery
Description: same-day bilateral cataract surgery with implantation of intraocular lens
Study NCT01036308 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pure fibre-product
Description: The subjects consumed 25 g pure fibre-product per day over two weeks. One half a portion of the fibres was stirred into a selected milk product and the other half in juice.
Study NCT00387998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AHRQ staying healthy booklet
Description: educational booklet about prevention
Study NCT00387998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk primer
Description: Know your chances booklet
Study NCT03752671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion of INTRASPINE device
Description: The surgical technique for excision of the disc hernia is the surgeon's usual technique: patient positioning (lying on his/her back or front or in the knee to chest position) the approach to the lumbar disc hernia (interlaminar or interspinous), closure and drainage of the operation site are performed by the surgeon's usual practice.~IntraSPINE® is positioned once surgery for the disc hernia has been performed. The implant bed is prepared with the assistance of the distractor provided. The choice of implant size is made after positioning the trial device corresponding to the anatomical bed. Once the size has been established the corresponding implant is placed in a cup of physiological saline prior to implantation. Implantation is performed using the appropriate implant holder.
Study NCT03752671 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Discectomy
Description: The surgical technique for excision of the disc hernia is the surgeon's usual technique: patient positioning (lying prone or supine or in the knee to chest position). The approach to the lumbar disc hernia (interlaminar or interspinous), closure and drainage of the operation site are performed using the surgeon's normal practice.
Study NCT03752671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discectomy
Description: The surgical technique for excision of the disc hernia is the surgeon's usual technique: patient positioning (lying prone or supine or in the knee to chest position). The approach to the lumbar disc hernia (interlaminar or interspinous), closure and drainage of the operation site are performed using the surgeon's normal practice.
Study NCT01615081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The acute effect of malt extract versus sucrose on the response of glucose and insulin, subjective appetite sensations and ad libitum energy intake
Description: 2-arm crossover study for investigation of the effect of malt extract vs. sucrose on glucose, insulin, subjective appetite sensations and ad libitum energy intake.
Study NCT01615081 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The acute effect of malt extract versus sucrose on the response of glucose and insulin, subjective appetite sensations and ad libitum energy intake
Description: 2-arm crossover study for investigation of the effect of malt extract vs. sucrose on glucose, insulin, subjective appetite sensations and ad libitum energy intake.
Study NCT02099500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction
Description: Liposuction using aspiration syringe and tumescent local anesthesia
Study NCT02099500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stem Cell Injection
Description: Stem cell implantation will be performed using intramuscular injection into the affected ischemic site of interest
Study NCT01474278 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose
Study NCT01474278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5028442
Description: Single dose
Study NCT03376594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benjakul Extract
Description: 30 patients taking Benjakul Extract dosage 100 mg capsule 3 times daily. before Breakfast, lunch and dinner for 42 days.
Study NCT03376594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loratadine
Description: 30 patients taking Loratadine dosage 10 mg capsule 3 times daily. before Breakfast, lunch and dinner for 42 days.
Study NCT02920164 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auricular acupuncture
Description: Auricular acupuncture with indwelling permanent needles
Study NCT02920164 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acupuncture
Description: Placebo acupuncture with placebo needles
Study NCT02946164 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stick To It
Description: The intervention is a prize system linked to points earned through online and real-world activities designed to incentivize young MSM to test for HIV and STIs every three months. Participants receive points for pre-determined activities, such as: answering online quizzes, inviting friends to participate, and getting tested for HIV/STIs. Points are redeemable in person at two AIDS Healthcare Foundation Men's Wellness Centers, where participants will be able to exchange their points for gumballs from a gumball machine; different color combinations of gumballs correspond to prizes of different values. Participants are reminded to get tested regularly via SMS messages; in addition, they can check when their next test is due by checking their testing timer on the stick2it.org website.
Study NCT02780778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Targeted therapy Apatinib：500 mg，po，qd
Study NCT02780778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: chemotherapy Docetaxel：60mg/m²，vein input 1hour，every 3w
Study NCT02737306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140
Description: PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
Study NCT02737306 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in parenteral solution.
Study NCT02736500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 28 GBq 177Lu-DOTATATE
Description: Patients without risk factors (particularly long standing and poorly controlled diabetes and hypertension) for late renal toxicity will be administered with 5 cycles of 5.5 GBq (150 mCi) each, up to the total cumulative activity of 28 GBq (750 mCi) of 177Lu-DOTATATE.
Study NCT02736500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 22 GBq 177Lu-DOTATATE
Description: Patients with risk factors for late renal toxicity will be administered with 6 cycles of 3.7 GBq (100 mCi) each, up to the total cumulative activity of 22 GBq (600 mCi)177Lu-DOTATATE
Study NCT05253560 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The investigators aim to identify prodromal PD in a cohort of carriers of Gaucher disease.
Description: Tests to help identify prodromal PD in a cohort of carriers of Gaucher disease
Study NCT05159635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Living programme and wearable technical aids
Description: attend 6 weeks active living programme and apply wearable technical aids for 8 weeks.
Study NCT05159635 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wearable technical aids
Description: apply wearable technical aids for 8 weeks.
Study NCT01036308 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: reference fibre
Description: The subjects consumed 25 g reference fibre (citrus fibre: Herbacel AQ Plus; Herbafood Ingredients) per day over two weeks. One half a portion of the fibres was stirred into a selected milk product and the other half in juice.
Study NCT00642902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Atacicept will be administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 32 weeks.
Study NCT00642902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Atacicept will be administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 32 weeks.
Study NCT00642902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Atacicept will be administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.
Study NCT00642902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched to atacicept
Description: Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
Study NCT03590600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ-043
Description: Powder and solvent for oral suspension
Study NCT03590600 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo: powder and solvent for oral suspension
Study NCT00901888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apelin infusion
Description: Infusion of up to 10picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.
Study NCT00901888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apelin infusion
Description: Infusion of up to 10picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.
Study NCT00901888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside infusion
Description: Infusion of up to 150-600picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.
Study NCT00901888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium nitroprusside infusion
Description: Infusion of up to 150-600picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.
Study NCT04034108 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical intervention combined with weight-supported ambulation training
Description: Surgeries were performed between 12 hours to 30 days after trauma. Internal fixation was implemented once instability of the injured spinal column was confirmed by radiology and exploration during operation. At 15 days after surgery, the patients were encouraged to start weight-supported ambulation training under careful protection by the trainers, the patients were encouraged to start weight-supported ambulation training under careful protection by the trainers. The training program was named Kunming Locomotor Training Program (KLTP)formulated by actively walking for a duration of 6 hours per day, 6 days per week for a minimum of 6 months.
Study NCT03156933 — intervention group
Intervention type: OTHER
Intervention: Assessment of splicing variants
Description: This is a biological study with primary samples without any intervention on patients.
Study NCT00846638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: Diagnostic assessment followed by a single session Brief Intervention with 3, 6, and 12 month follow-up
Study NCT00846638 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic assessment
Description: Single session diagnostic assessment with 12 month followup